<p>Jaguar Health Inc. 宣布已与 Iliad Research and Trading, L.P. 签署了两项交换协议，导致预先融资的普通股购买权证的发行。根据协议，Jaguar Health 发放了一份预先融资的权证，以购买 1,304,545 股普通股，以及另一份预先融资的权证，以购买额外的股份，行使价格均为每股 0.001 美元。这些权证可立即行使，但受益所有权上限为 9.99%。这些交易是以取消和退还 Iliad 之前持有的 91 股 M 系列优先股为交换完成的。这些权证的发行是在 1933 年证券法第 3(a)(9) 条款的注册豁免下进行的。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Jaguar Health Inc. 于 2025 年 12 月 12 日通过美国证券交易委员会（SEC）运营的电子数据收集、分析和检索系统 EDGAR 发布了用于生成本新闻简报的原始内容（参考 ID：0001193125-25-317693），并对此信息承担全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文档：这里</p>

JAGX

<p>Jaguar Health Inc. 已发行预融资认股权证，以换取 Iliad Research and Trading, L.P. 持有的 M 系列优先股的取消。这些认股权证允许以每股 $0.001 的价格立即行使，并设有 9.99% 的实益拥有权上限。该交易根据 1933 年证券法第 3(a)(9) 条款免于注册</p>

<p>Jaguar Health Inc. announced that it has entered into two exchange agreements with Iliad Research and Trading, L.P., resulting in the issuance of pre-funded common stock purchase warrants. Under the agreements, Jaguar Health issued a pre-funded warrant to purchase 1,304,545 shares of common stock and another pre-funded warrant to purchase additional shares, both at an exercise price of $0.001 per share. The warrants are exercisable immediately, subject to a beneficial ownership cap of 9.99%. These transactions were completed in exchange for the cancellation and retirement of 91 shares of Series M Preferred Stock previously held by Iliad. The issuance of these warrants was conducted under an exemption from registration pursuant to Section 3(a)(9) of the Securities Act of 1933. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-317693), on December 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>
<div class="lb-trans"><p>Jaguar Health Inc. 宣布已与 Iliad Research and Trading, L.P. 签署了两项交换协议，导致预先融资的普通股购买权证的发行。根据协议，Jaguar Health 发放了一份预先融资的权证，以购买 1,304,545 股普通股，以及另一份预先融资的权证，以购买额外的股份，行使价格均为每股 0.001 美元。这些权证可立即行使，但受益所有权上限为 9.99%。这些交易是以取消和退还 Iliad 之前持有的 91 股 M 系列优先股为交换完成的。这些权证的发行是在 1933 年证券法第 3(a)(9) 条款的注册豁免下进行的。免责声明：本新闻简报由公共技术公司（PUBT）使用生成性人工智能创建。虽然 PUBT 努力提供准确和及时的信息，但此 AI 生成的内容仅供参考，不应被解读为财务、投资或法律建议。Jaguar Health Inc. 于 2025 年 12 月 12 日通过美国证券交易委员会（SEC）运营的电子数据收集、分析和检索系统 EDGAR 发布了用于生成本新闻简报的原始内容（参考 ID：0001193125-25-317693），并对此信息承担全部责任。© 版权 2025 - 公共技术公司（PUBT）原始文档：这里</p>
</div>

捷豹健康公司发行预融资认股权证以换取优先股